Get the Stockscreener App
0.898
1.15%
-0.0013
After Hours:
.89
-0.008
-0.89%
Imunon Inc stock is traded at $0.898, with a volume of 110.34K.
It is down -1.15% in the last 24 hours and down -9.27% over the past month.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
See More
Previous Close:
$0.8993
Open:
$0.89
24h Volume:
110.34K
Relative Volume:
0.44
Market Cap:
$12.91M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-0.4751
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
+0.45%
1M Performance:
-9.27%
6M Performance:
-16.92%
1Y Performance:
+61.64%
1-Day Range:
$0.8712
$0.914
1-Week Range:
$0.86
$0.9699
52-Week Range:
$0.48
$3.65
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
0.898 | 12.91M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.09 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
709.77 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.69 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Imunon Inc Stock (IMNN) Latest News
Imunon director Donald Braun acquires $29,480 worth of shares - MSN
Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewswire
IMUNON Secures FDA Alignment for Phase 3 Ovarian Cancer Immunotherapy Manufacturing Strategy - StockTitan
Imunon, Inc. (NASDAQ:IMNN) Short Interest Update - Defense World
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - The Manila Times
IMUNON Announces Continued Strong Improvement in Overall - GlobeNewswire
IMUNON's Ovarian Cancer Drug Shows Improved Survival Data in Phase 2 Trial, Phase 3 Planned - StockTitan
Critical Review: Sernova (OTCMKTS:SEOVF) & Imunon (NASDAQ:IMNN) - Defense World
Imunon faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Imunon faces Nasdaq delisting over share price rule - Investing.com
D. Boral Capital Reaffirms Buy Rating for Imunon (NASDAQ:IMNN) - Defense World
Imunon shares hold as analyst backs stock target, buy rating post FDA meet - Investing.com UK
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001 - Smartkarma
Imunon announces results from End-of-Phase 2 meeting with FDA for IMNN-001 - TipRanks
IMUNON Announces Results from its End-of-Phase 2 Meeting - GlobeNewswire
IMUNON's Cancer Drug Shows 35% Survival Boost, FDA Backs Phase 3 Trial | IMNN Stock News - StockTitan
FY2024 EPS Estimates for Imunon Boosted by Zacks Small Cap - Defense World
Analysts Set Expectations for Imunon Q1 Earnings - Defense World
Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Imunon reveals promising ovarian cancer study results - Investing.com India
Earnings call: Imunon reveals promising ovarian cancer study results By Investing.com - Investing.com UK
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... - Yahoo Finance
Imunon, Inc. Reports Q3 2024 Earnings and Progress - TipRanks
Imunon Inc (IMNN) Quarterly 10-Q Report - Quartzy
Imunon presents data from Phase 2 OVATION 2 clinical trial - TipRanks
IMUNON Presents Positive Data from Phase 2 OVATION 2 - GlobeNewswire
IMUNON's Cancer Drug Shows 35% Survival Boost in Phase 2 Ovarian Cancer Trial | IMNN Stock News - StockTitan
Imunon sees cash runway into 3Q25 - TipRanks
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
IMUNON INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Imunon (IMNN) to Release Quarterly Earnings on Thursday - MarketBeat
IMUNON to Hold Third Quarter 2024 Financial Results and - GlobeNewswire
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - Yahoo Finance
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of - GlobeNewswire
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - Marketscreener.com
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - Yahoo Finance
Imunon’s stock rockets after ovarian cancer treatment’s positive trial results - MSN
Imunon reports inducement grant under NASDAQ listing rule - Yahoo Finance
Ex-Allstate Atty Named Biotech Co.'s General Counsel - Law360
Imunon Welcomes Susan Eylward as General Counsel, Strengthens Leadership Team - TipRanks
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary - Marketscreener.com
Imunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy” - Defense World
Imunon (NASDAQ:IMNN) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton sets stock target on Imunon, initiates with buy rating - Investing.com Canada
Ratio Review: Analyzing Imunon Inc (IMNN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Imunon Inc Stock (IMNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lindborg Stacy | President and CEO |
Aug 15 '24 |
Buy |
0.98 |
25,000 |
24,500 |
264,166 |
| Tardugno Michael H | Executive Chairman of Board |
Aug 15 '24 |
Buy |
1.03 |
25,000 |
25,750 |
353,346 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):